Skip to main content
PharmaSGP Holding SE logo

PharmaSGP Holding SE — Investor Relations & Filings

Ticker · PSG ISIN · DE000A2P4LJ5 LEI · 3912005CZ12PVVCIPT91 F Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2024-05-28 Interim / Quarterly Rep…
Country DE Germany
Listing F PSG

About PharmaSGP Holding SE

https://pharmasgp.com/english/

PharmaSGP Holding SE is a pharmaceutical company specializing in the development and marketing of a broad portfolio of over-the-counter (OTC) drugs and other healthcare products. The company focuses on pharmacy-exclusive products for chronic indications, primarily utilizing natural active ingredients with a favorable side-effect profile. It holds a market-leading position in several therapeutic areas, particularly in systemic, chemical-free pain remedies with its RubaXX® (rheumatic pain) and Restaxil® (nerve pain) brand families. The portfolio also includes prominent brands such as Baldriparan® (natural sleep aid), Formigran® (migraine), Spalt® (general pain), and DESEO® and NERADIN® (sexual weakness).

Recent filings

Filing Released Lang Actions
Q1 statement / Q1 financial report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Statement Q1 2024' and contains comprehensive financial data, including consolidated statements of profit or loss, balance sheet summaries, and cash flow analysis for the first quarter of 2024. It provides a detailed management discussion and analysis of the company's performance, fitting the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-28 English
PharmaSGP continues dynamic business development with significant revenues growth in Q1 2024
Earnings Release Classification · 100% confidence The document is a news release dated May 14, 2024, titled "PharmaSGP continues dynamic business development with significant revenues growth in Q1 2024." It explicitly states it is based on "preliminary, unaudited figures" and provides key financial highlights for the first quarter (Q1 2024), including revenues (€30.1 million) and adjusted EBITDA (€8.9 million). It also mentions the expected publication date for the full statement (May 28, 2024). This structure—a brief announcement of key period results before the full report is released—is characteristic of an Earnings Release (ER). It is not the comprehensive Interim Report (IR) itself, nor is it a transcript (CT) or a full Annual Report (10-K). Q1 2024
2024-05-14 English
Annual financial report 2023
Annual Report Classification · 100% confidence The document is a comprehensive annual report for PharmaSGP for the fiscal year 2023. It contains a table of contents, management board forewords, a combined management report, consolidated financial statements, and an independent auditor's report. It is clearly the full annual report, not an announcement or a summary, as it includes detailed financial tables, notes to the financial statements, and governance disclosures. FY 2023
2024-04-29 English
Report Publication Announcement 2024
Report Publication Announcement Classification · 100% confidence The document is a preliminary announcement regarding the future publication of financial reports, specifically mentioning 'Annual financial report' and 'Annual financial report of the group', with disclosure dates set for April 29, 2024. The document itself does not contain the full financial report but serves as a notice that the report will be made public soon, providing links where it will be available. According to Rule 2 (The 'MENU VS MEAL' Rule), a short document announcing the publication of a report should be classified as a Report Publication Announcement (RPA). The document explicitly states it is a 'Preliminary announcement of the publication of financial reports'.
2024-04-22 English
PharmaSGP Holding SE proposes an increased dividend of EUR 1.36 per share for 2023
Notice of Dividend Amount Classification · 100% confidence The document is an 'Ad-hoc' announcement dated April 18, 2024, explicitly stating that the Management Board and Supervisory Board will propose an increased dividend of EUR 1.36 per share for the 2023 financial year to the upcoming Annual General Meeting (AGM). This content directly relates to the announcement of a dividend amount and details for shareholders, fitting the definition for 'Notice of Dividend Amount' (DIV). Although it mentions the AGM, the primary focus is the dividend proposal itself, not the AGM materials (AGM-R) or the voting results (DVA). It is a specific financial action announcement, not a general regulatory filing (RNS).
2024-04-18 English
PharmaSGP exceeds the 100 million revenues mark in 2023 and plans further profitable growth in 2024
Earnings Release Classification · 100% confidence The document is an announcement dated April 16, 2024, detailing preliminary, unaudited financial results for the 2023 financial year, including revenues (€101.1 million) and adjusted EBITDA (€34.1 million). It also provides a forecast for 2024. The key indicator is the phrase: 'PharmaSGP will publish its full annual report for 2023 on 29 April, 2024.' This indicates the current document is a preliminary release of results, not the final, comprehensive report (10-K) or the full audit report (AR). It contains key financial highlights and management commentary, fitting the definition of an Earnings Release (ER). It is not a short announcement linking to a report, as it contains substantial preliminary data itself, thus ruling out RPA/RNS based on the 'Menu vs Meal' rule. FY 2023
2024-04-16 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.